Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Blue light more sensitive than white light cystoscopy for bladder cancer surveillance

23 Dec 2017

Office-based blue light flexible cystoscopy (BLFC) significantly improves detection of patients with recurrent bladder cancer and is safe when performed for surveillance compared white light flexible cystoscopy (WLFC), as shown in a recent study.

Additionally, performing blue light cystoscopy (BLC) in the operating room (OR) significantly boosts detection of carcinoma in situ (CIS), as well as identifies lesions missed with white light cystoscopy (WLC).

The phase III multicentre study compared BLFC with WLFC in the detection of bladder cancer recurrence during surveillance. A total of 304 nonmuscle invasive bladder cancer patients received intravesical hexaminolevulinate before WLFC and BLFC. Those found to have suspicious lesions were referred to the OR for repeat WLC and BLC. All suspected lesions were biopsied or resected, with specimens examined by an independent pathology consensus panel.

The primary endpoint was the proportion of patients with histologically confirmed malignancy detected only with BLFC. Additional endpoints included false positive rate, detection of CIS, and additional tumours detected only with BLC.

Following surveillance, 103 patients were referred to the OR. Of these patients, 63 had confirmed malignancy, including 26 with CIS. Recurrence was detected only with BLFC in 13 of 63 patients (20.6 percent; p<0.0001), and five of these patients had confirmed CIS.

From the OR examination, 26 of 63 patients (41 percent) had confirmed CIS, with nine cases (34.6 percent) detected only with BLC (p<0.0001). BLC identified additional malignant lesions in 29 patients (46 percent).

False positive rates were similar between WLC and BLC (9.1 percent). There were 12 adverse events reported during surveillance, but none of which were serious.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 4 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 2 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.